Onconetix, Inc. Research and Development Expense
Onconetix, Inc. (ONCO) reported Research and Development Expense of $24.45 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-06-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-06-12
- Onconetix, Inc. research and development expense for the quarter ending 2025-03-31 was $24.45K, a 50.06% decline year-over-year.
- Onconetix, Inc. research and development expense for the quarter ending 2024-12-31 was -$290.00.
- Onconetix, Inc. research and development expense for the quarter ending 2024-09-30 was $109.36K, a 50.12% decline year-over-year.
- Onconetix, Inc. research and development expense for the quarter ending 2024-03-31 was $48.96K, a 95.48% decline year-over-year.
- Onconetix, Inc. research and development expense for fiscal 2024 was $154.36K, a 92.08% decline from fiscal 2023.
- Onconetix, Inc. research and development expense for fiscal 2023 was $1.95M, a 52.80% decline from fiscal 2022.
- Onconetix, Inc. research and development expense for fiscal 2022 was $4.13M, a 211.67% increase from fiscal 2021.
- Onconetix, Inc. research and development expense for fiscal 2021 was $1.33M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-03-31 | $24.45K 10-Q · filed 2025-06-12 | $24.16K derived: sum of 2 quarters · filed 2025-06-12 | $133.53K derived: sum of 3 quarters · filed 2025-06-12 | |
| 2024-12-31 | -$290.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | $109.08K derived: sum of 2 quarters · filed 2025-06-02 | $154.36K 10-K · filed 2025-06-02 | |
| 2024-09-30 | $109.36K 10-Q · filed 2024-12-10 | $154.65K 10-Q · filed 2024-12-10 | ||
| 2024-03-31 | $48.96K 10-Q · filed 2025-06-12 | -$149.96K derived: sum of 2 quarters · filed 2025-06-12 | $69.28K derived: sum of 3 quarters · filed 2025-06-12 | $916.13K derived: sum of 4 quarters · filed 2025-06-12 |
| 2023-12-31 | -$198.92K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | $20.32K derived: sum of 2 quarters · filed 2025-06-02 | $867.17K derived: sum of 3 quarters · filed 2025-06-02 | $1.95M 10-K · filed 2025-06-02 |
| 2023-09-30 | $219.24K 10-Q · filed 2024-12-10 | $1.07M derived: sum of 2 quarters · filed 2024-12-10 | $2.15M 10-Q · filed 2024-12-10 | $3.35M derived: sum of 4 quarters · filed 2024-12-10 |
| 2023-06-30 | $846.85K 10-Q · filed 2023-10-20 | $1.93M 10-Q · filed 2023-10-20 | $3.13M derived: sum of 3 quarters · filed 2024-05-20 | $4.31M derived: sum of 4 quarters · filed 2024-05-20 |
| 2023-03-31 | $1.08M 10-Q · filed 2024-05-20 | $2.29M derived: sum of 2 quarters · filed 2024-05-20 | $3.46M derived: sum of 3 quarters · filed 2024-05-20 | $4.76M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | $2.38M derived: sum of 2 quarters · filed 2024-04-11 | $3.67M derived: sum of 3 quarters · filed 2024-04-11 | $4.13M 10-K · filed 2024-04-11 |
| 2022-09-30 | $1.18M 10-Q · filed 2023-11-17 | $2.47M derived: sum of 2 quarters · filed 2023-11-17 | $2.92M 10-Q · filed 2023-11-17 | $3.36M derived: sum of 4 quarters · filed 2023-11-17 |
| 2022-06-30 | $1.29M 10-Q · filed 2023-10-20 | $1.75M 10-Q · filed 2023-10-20 | $2.19M derived: sum of 3 quarters · filed 2023-10-20 | $2.46M derived: sum of 4 quarters · filed 2023-10-20 |
| 2022-03-31 | $455.09K 10-Q · filed 2023-05-12 | $892.42K derived: sum of 2 quarters · filed 2023-05-12 | $1.16M derived: sum of 3 quarters · filed 2023-05-12 | $1.69M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $437.33K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $707.25K derived: sum of 2 quarters · filed 2023-03-09 | $1.24M derived: sum of 3 quarters · filed 2023-03-09 | $1.33M 10-K · filed 2023-03-09 |
| 2021-09-30 | $269.93K 10-Q · filed 2022-11-14 | $799.47K derived: sum of 2 quarters · filed 2022-11-14 | $887.70K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $529.54K 10-Q · filed 2022-08-15 | $617.78K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $88.24K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |